Kairos Pharma (NYSEAMERICAN:KAPA) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research note issued to investors on Monday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

Separately, Maxim Group assumed coverage on shares of Kairos Pharma in a research note on Thursday, March 27th. They issued a “buy” rating and a $4.00 price objective on the stock.

Kairos Pharma Trading Up 1.6 %

KAPA opened at $0.94 on Monday. Kairos Pharma has a 52-week low of $0.85 and a 52-week high of $4.00. The company’s 50-day moving average is $1.29.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.